Borregaard Q2 2026 slides: stable EBITDA masks divergent segment trends

Borregaard shares rose more than 5% to about $159 after reporting Q2 2026 operating revenues up 3% YoY to NOK 2,114M and EBITDA essentially flat at NOK 515M (margin 24.4% vs 25.5%), despite a reported net EPS of NOK -1.27 due to NOK 337M Alginor impairment and NOK 30M site accruals. Underlying adjusted EPS was NOK 2.35, while operating cash flow surged to NOK 695M (vs NOK 385M) as net working capital improved; leverage stayed low at 1.20x and liquidity totaled NOK 3,948M. Guidance was mixed—BioSolutions sales volume cut to ~335k tonnes from 340k, while BioMaterials sales volume raised to >160k tonnes—and the company launched a NOK 150M annual cost-savings program.

Analysis

The market is reacting to earnings quality, not reported EPS. Core EBITDA held up despite FX and input-cost pressure, and the cash conversion suggests the business is still generating more economic profit than the headline loss implies. The impairment reads more like a capital-allocation cleanup than an operating stumble, but it also signals management is becoming more disciplined about non-core investments.

Competitive dynamics look better in the most differentiated parts of the portfolio than in the commodity-adjacent ones. If Borregaard can keep taking volume while translating lower NOK pricing into stable margins, that implies share gain or defensible share in specialty grades, while smaller European specialty-chemical peers with less scale and worse FX hedging should feel the squeeze first. The weak spot is the lower-value mix in BioSolutions, where pricing and energy sensitivity make the earnings base less durable if the krone stays firm.

Near term, the stock may be a little ahead of the fundamentals after the gap higher because the visible catalysts are still mostly back-end loaded: the cost program is a multi-year margin tailwind, not a next-quarter fix. Over 1-3 months, the key test is whether specialty-grade volumes stay elevated and whether the segment mix stabilizes; over 6-18 months, debottlenecking and lower wood costs should matter more than the one-time write-offs. The contrarian risk is that operating cash flow was flattered by working-capital release, so if that normalizes while FX remains a headwind, the current rerating could prove premature.

Key Decisions for Investors

• Do not chase the post-print move in BRGAY; wait for a 2-4% pullback to initiate a tactical long, because the rerating depends on 2027-28 savings rather than near-term EPS momentum.
• For a relative-value expression, consider long BRGAY vs short XLB on a 1-3 month horizon: Borregaard’s specialty mix and balance-sheet strength should outperform a broader chemical basket if the macro turns more cost-sensitive.
• Set an alert on Q3 guidance execution: if specialty-grade volumes fail to hold near the implied ~40k tonne run-rate or BioSolutions falls below the 335k full-year path, treat the thesis as broken and reduce exposure.
• If liquidity is a concern, use BRGAY only in smaller size or via the most liquid local line available; the story is more suitable for patient capital than for a momentum trade.